Literature DB >> 15707852

Sildenafil selectively inhibits acute pulmonary embolism-induced pulmonary hypertension.

Carlos A Dias-Junior1, Tadeu F Vieira, Heitor Moreno, Paulo R Evora, Jose E Tanus-Santos.   

Abstract

Selective pulmonary vasodilators attenuate acute pulmonary embolism (APE)-induced pulmonary hypertension. We examined the effects of intravenous sildenafil on the hemodynamic and respiratory changes caused by APE in anesthetized dogs. Sham operated animals (n=3) received only saline infusions. APE was induced by intravenous injections of microspheres in amounts adjusted to increase mean pulmonary artery pressures (MPAP) by 20 mmHg. Hemodynamic evaluation was performed and arterial blood samples were drawn for blood gas analysis at baseline, 15 and 30 min after APE was induced, and then 15, 30, and 45 min after the sildenafil infusion (1 mg kg(-1) infused intravenously in 15 min followed by 0.3 mg kg(-1) h(-1) for 30 min) started in the Sildenafil group (n=7), or saline infusion started in the control group (n=8). APE induced sustained pulmonary hypertension and 325% increase in pulmonary vascular resistance index (PVRI) without significant changes in the other hemodynamic parameters. While the animals in the control group showed no further changes in MPAP and PVRI, a significant decrease in MPAP and PVRI (-25 and -45%, respectively; P<0.05 both) was observed with sildenafil. No significant changes in the other hemodynamic parameters were observed in both groups. APE decreased PaO2, whereas sildenafil attenuated the decrease in PaO2 (P<0.05). We conclude that intravenous sildenafil can selectively attenuate the increases in MPAP and PVRI after APE.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15707852     DOI: 10.1016/j.pupt.2004.11.010

Source DB:  PubMed          Journal:  Pulm Pharmacol Ther        ISSN: 1094-5539            Impact factor:   3.410


  7 in total

Review 1.  Endothelial nanomedicine for the treatment of pulmonary disease.

Authors:  Jacob S Brenner; Colin Greineder; Vladimir Shuvaev; Vladimir Muzykantov
Journal:  Expert Opin Drug Deliv       Date:  2014-11-14       Impact factor: 6.648

2.  The use of sildenafil in the therapy of massive pulmonary embolism.

Authors:  Carlos A Dias-Junior
Journal:  Intensive Care Med       Date:  2006-06-21       Impact factor: 17.440

3.  No effect of epoprostenol on right ventricular diameter in patients with acute pulmonary embolism: a randomized controlled trial.

Authors:  Albertus J Kooter; Richard G Ijzerman; Otto Kamp; Anco B Boonstra; Yvo M Smulders
Journal:  BMC Pulm Med       Date:  2010-03-30       Impact factor: 3.317

4.  Losartan exerts no protective effects against acute pulmonary embolism-induced hemodynamic changes.

Authors:  Carlos A Dias; Evandro M Neto-Neves; Marcelo F Montenegro; Jose E Tanus-Santos
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-10-02       Impact factor: 3.000

5.  Dramatic beneficial effects of sildenafil in recurrent massive pulmonary embolism.

Authors:  Vincent Ganière; François Feihl; Damien Tagan
Journal:  Intensive Care Med       Date:  2006-02-01       Impact factor: 17.440

Review 6.  Pivotal effects of phosphodiesterase inhibitors on myocyte contractility and viability in normal and ischemic hearts.

Authors:  Yuan James Rao; Lei Xi
Journal:  Acta Pharmacol Sin       Date:  2008-12-08       Impact factor: 6.150

7.  ACVIM consensus statement guidelines for the diagnosis, classification, treatment, and monitoring of pulmonary hypertension in dogs.

Authors:  Carol Reinero; Lance C Visser; Heidi B Kellihan; Isabelle Masseau; Elizabeth Rozanski; Cécile Clercx; Kurt Williams; Jonathan Abbott; Michele Borgarelli; Brian A Scansen
Journal:  J Vet Intern Med       Date:  2020-02-17       Impact factor: 3.333

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.